EyeBio CEO David Guyer (L) and CSO Anthony Adamis
EyeBio doubles the size of its Series A as anti-VEGF veterans seek new ways of treating retinal diseases
Retinal disease biotech EyeBio has doubled the size of its initial Series A raise from February 2022. With another $65 million …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
